Rehabilitation Therapy Services Market to Surpass USD 64.3 Billion by 2034, Driven by Rising Chronic Diseases and Technological Advancements

Rehabilitation Therapy Services Market to Surpass USD 64.3 Billion by 2034, Driven by Rising Chronic Diseases and Technological Advancements The global rehabilitation therapy services market size is calculated at USD 31.88 billion in 2025 and is expected to reach around USD 64.32 billion by 2034, growing at a CAGR of 8.24% for the forecasted period. […]

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates GlobeNewswire November 12, 2025 Company reports Q3 2025 AUCATZYL(R) net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of target Clinical execution and data generation to support market growth and expansion continues; data in severe

DAVIDsTEA Announces $3.0 Million Private Placement and $2.7 Million Revenue-Linked Financing

DAVIDsTEA Announces $3.0 Million Private Placement and $2.7 Million Revenue-Linked Financing GlobeNewswire November 12, 2025 Pembroke Heritage Fund Limited, Pembroke Genesis Pooled Fund and a related party subscribe for $1.5 million in private placement Jane Silverstone Segal, Chair of the Board of DAVIDsTEA, also subscribes for $1.5 million Proceeds will be used to fund new

Home Resource Becomes Exclusive US Distributor of Kettnaker Soma Media System

Home Resource Becomes Exclusive US Distributor of Kettnaker Soma Media System GlobeNewswire November 12, 2025 Sarasota, FL , Nov. 12, 2025 (GLOBE NEWSWIRE) — Home Resource, Sarasota's premier destination for luxury furniture and contemporary European design, proudly announces its designation as the exclusive U.S. distributor of the Kettnaker Soma Media System, a revolutionary modular media

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights GlobeNewswire November 12, 2025 Phase 1b trial in Alzheimer's disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolled PMN310 continues to demonstrate a favorable safety profile On track to report 6-month interim data in Q2 2026 and final 12-month top-line results

Prospect Credit REIT Provides $18.0 Million to Class A Stabilized Cash-Flowing Multifamily Property in New Rochelle, NY

Prospect Credit REIT Provides $18.0 Million to Class A Stabilized Cash-Flowing Multifamily Property in New Rochelle, NY GlobeNewswire November 12, 2025 NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — Prospect Credit REIT, LLC (“PCRED”), a non-traded real estate fund focused on real estate credit managed by an affiliate of Prospect Capital Management L.P. (“Prospect”), has

Independent Analysis Confirms HPQ Fumed Silica Reactor Produces Commercial-Grade Material at Pilot Scale

Independent Analysis Confirms HPQ Fumed Silica Reactor Produces Commercial-Grade Material at Pilot Scale HPQ achieves a key milestone toward commercial production, producing commercial-grade fumed silica with superior surface area and purity in a single step at pilot scale GlobeNewswire November 12, 2025 MONTREAL, Nov. 12, 2025 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the

Fancamp Announces New Partnership With Harfang and Initiation of Strategic Corporate Reorganization

Fancamp Announces New Partnership With Harfang and Initiation of Strategic Corporate Reorganization GlobeNewswire November 12, 2025 VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) — Fancamp Exploration Ltd. (“Fancamp” or the “Corporation“) (TSX Venture Exchange: FNC) is pleased to announce that it has signed an option agreement with Harfang Exploration Inc. (“Harfang“), whereby Fancamp, subject

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights GlobeNewswire November 12, 2025 Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK(R), the first known therapy within the emerging deep B-cell depletion category to receive

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results GlobeNewswire November 12, 2025 Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of Directors Next-generation GABA-aminotransferase (GABA-AT) inhibitor, OV329, demonstrated strong inhibitory activity and a

Scroll to Top